Literature DB >> 21865317

Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease.

Penelope G Foulds1, J Douglas Mitchell, Angela Parker, Roisin Turner, Gerwyn Green, Peter Diggle, Masato Hasegawa, Mark Taylor, David Mann, David Allsop.   

Abstract

Parkinson's disease (PD) is characterized by the presence of Lewy bodies containing phosphorylated and aggregated α-synuclein (α-syn). α-Syn is present in human body fluids, including blood plasma, and is a potential biomarker for PD. Immunoassays for total and oligomeric forms of both normal and phosphorylated (at Ser-129) α-syn have been used to assay plasma samples from a longitudinal cohort of 32 patients with PD (sampled at mo 0, 1, 2, 3), as well as single plasma samples from a group of 30 healthy control participants. The levels of α-syn in plasma varied greatly between individuals, but were remarkably consistent over time within the same individual with PD. The mean level of phospho-α-syn was found to be higher (P=0.053) in the PD samples than the controls, whereas this was not the case for total α-syn (P=0.244), oligo-α-syn (P=0.221), or oligo-phospho-α-syn (P=0.181). Immunoblots of plasma revealed bands (at 21, 24, and 50-60 kDa) corresponding to phosphorylated α-syn. Thus, phosphorylated α-syn can be detected in blood plasma and shows more promise as a diagnostic marker than the nonphosphorylated protein. Longitudinal studies undertaken over a more extended time period will be required to determine whether α-syn can act as a marker of disease progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21865317     DOI: 10.1096/fj.10-179192

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  77 in total

Review 1.  GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

Authors:  Parker H Johnson; Neal J Weinreb; James C Cloyd; Paul J Tuite; Reena V Kartha
Journal:  Mol Genet Metab       Date:  2019-10-23       Impact factor: 4.797

Review 2.  [Early recognition of Parkinson's disease. Objectifiable non-motor symptoms and biomarkers].

Authors:  B Mollenhauer; F Sixel-Döring; A Storch; C Schneider; R Hilker; E Kalbe
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

3.  Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study.

Authors:  Hua Wang; Anzari Atik; Tessandra Stewart; Carmen Ginghina; Patrick Aro; Kathleen F Kerr; John Seibyl; Danna Jennings; Poul Henning Jensen; Kenneth Marek; Min Shi; Jing Zhang
Journal:  Neurobiol Dis       Date:  2018-04-27       Impact factor: 5.996

4.  Serological Analysis of Alpha-synuclein and NF-κB in Parkinson's Disease Patients.

Authors:  Vineeta Gupta; Ravindra Kumar Garg; Sanjay Khattri
Journal:  J Clin Diagn Res       Date:  2015-05-01

5.  Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis.

Authors:  Anastasia Bougea; Leonidas Stefanis; George P Paraskevas; Evangelia Emmanouilidou; Kostas Vekrelis; Elisabeth Kapaki
Journal:  Neurol Sci       Date:  2019-02-04       Impact factor: 3.307

6.  A new approach: information gain algorithm-based k-nearest neighbors hybrid diagnostic system for Parkinson's disease.

Authors:  Cüneyt Yücelbaş
Journal:  Phys Eng Sci Med       Date:  2021-04-14

7.  Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein.

Authors:  Dominique Bétemps; Jérémy Verchère; Anne-Laure Mougenot; Ingolf Lachmann; Eric Morignat; Emilie Antier; Latifa Lakhdar; Stéphane Legastelois; Thierry Baron
Journal:  J Vis Exp       Date:  2015-05-30       Impact factor: 1.355

Review 8.  Gender differences in Parkinson's disease: focus on plasma α-synuclein.

Authors:  Giovanni Caranci; Paola Piscopo; Roberto Rivabene; Anna Traficante; Barbara Riozzi; Anna Elisa Castellano; Stefano Ruggieri; Nicola Vanacore; Annamaria Confaloni
Journal:  J Neural Transm (Vienna)       Date:  2013-01-18       Impact factor: 3.575

Review 9.  Potential of Extracellular Vesicles in Neurodegenerative Diseases: Diagnostic and Therapeutic Indications.

Authors:  Mehrnaz Izadpanah; Arshia Seddigh; Somayeh Ebrahimi Barough; Seyed Abolhassan Shahzadeh Fazeli; Jafar Ai
Journal:  J Mol Neurosci       Date:  2018-08-23       Impact factor: 3.444

Review 10.  Is there a need to redefine Parkinson's disease?

Authors:  Philipp Mahlknecht; Werner Poewe
Journal:  J Neural Transm (Vienna)       Date:  2013-05-29       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.